中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Issue 12
Dec.  2016
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2016  >  32(12): 2337-2341

Clinical effect and safety of percutaneous radiofrequency ablation following transcatheter arterial chemoembolization in treatment of primary liver cancer in high-risk locations

DOI: 10.3969/j.issn.1001-5256.2016.12.021
Research funding:

 

  • Published Date: 2016-12-20
    Abstract
  • Objective To investigate the clinical effect and safety of percutaneous radiofrequency ablation( RFA) following transcatheter arterial chemoembolization( TACE) in the treatment of primary liver cancer in high- risk locations. Methods The patients with primary liver cancer in high- risk locations who were diagnosed and treated from January 2011 to December 2015 were enrolled. All the patients underwent TACE followed by CT- guided RFA 3- 5 days later. The treatment outcome and adverse events were observed. Results A total of64 patients with 76 lesions were enrolled and all of them completed TACE and RFA. At one month after surgery,the complete tumor ablation rate was 81. 5%( 62/76). The patients were followed up for 6 to 64 months after surgery; at the end of follow- up,the local tumor progression rate was 28. 9%( 22/76),and the 1-,2-,and 3- year survival rates were 90. 6%,78. 1%,and 64. 1%,respectively. The incidence rate of severe surgical complications during follow- up was 3. 1%( one patient each experienced liver abscess and hematobilia),and the patients achieved remission after medical treatment and interventional treatment without any sequel. Conclusion CT- guided RFA after TACE is a safe and feasible regimen for primary liver cancer in high- risk locations.

     

    • FullText(HTML)
    • References(18)
  • [1]WANG Y,LUO Q,LI Y,et al.Radiofrequency ablation versus hepatic resection for small hepatocellular carcinomas:a meta-analysis of randomized and non randomized controlled trials[J].PLo S One,2014,9(1):e84484.
    [2]TERATANI T,YOSHIDA H,SHIINA S,et al.Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations[J].Hepatology,2006,43(5):1101-1108.
    [3]LIU LL.The development of radiofrequency ablation of hepatic carcinoma in high-risk locations[J].Chin Clin Oncol,2012,17(5):475-478.(in Chinese)刘丽莉.高危部位肝癌射频消融治疗的进展[J].临床肿瘤学杂志,2012,17(5):475-478.
    [4]Ministry of Health of the People’s Republic of China.Diagnosis,management,and treatment of hepatocellular carcinoma(V2011)[J].J Clin Hepatol,2011,27(11):1141-1159.(in Chinese)中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版)[J].临床肝胆病杂志,2011,27(11):1141-1159.
    [5]BRUIX J,SHERMAN M,LLOVET JM,et al.Clinical management of hepatocellular carcinoma.Conclusions of the Barcelona-2000 EASL conference.European Association for the Study of the Liver[J].J Hepatol,2001,35(3):421-430.
    [6]GOLDBERG SN,CHARBONEAU JW,DODD GD,et al.Imageguided tumor ablation:proposal for standardization of terms and reporting criteria[J].Radiology,2003,228(2):335-345.
    [7]de LIMA LOPES GJR,DICKSEY JS,PETERS WP,et al.Final results of a prematurely discontinued phase 1/2 study of eniluracil with escalating doses of 5-fluorouracil administered orally in patients with advanced hepatocellular carcinoma[J].Cancer Chemother Pharmacol,2011,68(4):1067-1073.
    [8]GAZELLE GS,GOLDBERG SN,SOLBIATI L,et al.Tumor ablation with radio-frequency energy[J].Radiology,2000,217(3):633-646.
    [9]WONG SN,LIN CJ,LIN CC,et al.Combined percutaneous radiofrequency ablation and ethanol injection for hepatocellular carcinoma in high-risk locations[J].AJR Am J Roentgenol,2008,190(3):w187-195.
    [10]CHA DI,LEE MW,RHIM H,et al.Therapeutic efficacy and safety of percutaneous ethanol injection with or without combined radiofrequency ablation for hepatocellular carcinomas in high risk locations[J].Korean J Radiol,2013,14(2):240-247.
    [11]LIN JW,LIN CC,CHEN WT,et al.Combining radiofrequency ablation and ethanol injection may achieve comparable long-term outcomes in larger hepatocellular carcinoma(3.1-4cm)and in high-risk locations[J].Kaohsiung J Med Sci,2014,30(8):396-401.
    [12]KELOGRIGORIS M,LASPAS F,KYRKOU K,et al.Percutaneous radiofrequency ablation for malignant liver tumours in challenging locations[J].J Med Imaging Radiat Oncol,2012,56(1):48-54.
    [13]YAMANAKA T,YAMAKADO K,TAKAKI H,et al.Ablative zone size created by radiofrequency ablation with and without chemoembolization in small hepatocellular carcinomas[J].Jpn J Radiol,2012,30(7):553-559.
    [14]ZHANG L,YIN X,GAN YH,et al.Radiofrequency ablation following first-line transarterial chemoembolization for patients with unresectable hepatocellular carcinoma beyond the Milan criteria[J].BMC Gastroenterol,2014,14(1):11.
    [15]YI Y,ZHANG Y,WEI Q,et al.Radiofrequency ablation or microwave ablation combined with transcatheter arterial chemoembolization in treatment of hepatocellular carcinoma by comparing with radiofrequency ablation alone[J].Chin J Cancer Res,2014,26(1):112-118.
    [16]DU JK,ZHANG MD,ZOU Y,et al.Large dose heat lipiodol TACE combined with radiofrequency ablation in treatment of hepatic metastases of digestive tract cancer[J].Clin J Med Offic,2014,42(9):898-900.(in Chinese)独建库,张明德,邹洋,等.大剂量热碘的TACE联合射频消融术治疗消化道癌肝转移[J].临床军医杂志,2014,42(9):898-900.
    [17]BILCHIK AJ,WOOD TF,ALLEGRA D,et al.Cryosurgical ablation and radiofrequency ablation for unresectable hepatic malignant neoplasms:a proposed algorithm[J].Arch Surg,2000,135(6):657-662.
    [18]LI M,LI ZY,TIAN JK,et al.Clinical study of ultrasound-guided percutaneous radiofrequency ablation for primary hepatic carcinoma adjacent to the diaphragm[J].J Clin Hepatol,2015,31(4):573-577.(in Chinese)李猛,李志艳,田江克,等.超声引导经皮射频消融对邻近横膈部原发性肝癌治疗的有效性与安全性评价[J].临床肝胆病杂志,2015,31(4):573-577.
    • Relative Articles

  • Relative Articles

    [1]Kuan LI, Huibin NING, Huiming JIN, Zhen PENG, Jia SHANG. Effect of pegylated interferon α-2b on serum HBsAg clearance rate in treatment of patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2023, 39(8): 1819-1824. doi: 10.3969/j.issn.1001-5256.2023.08.009
    [2]Peiyao FAN, Fuchuan WANG, Yinjie GAO, Zhiqiang XU, Yi DONG, Jianguo YAN, Lili CAO, Danni FENG, Yanwei ZHONG, Min ZHANG. Value of serum PreS1 in early prediction of HBsAg clearance after IFN-α treatment in children with HBeAg-positive chronic hepatitis B[J]. Journal of Clinical Hepatology, 2023, 39(8): 1825-1831. doi: 10.3969/j.issn.1001-5256.2023.08.010
    [3]Wei ZHU, Xiaoyong ZHANG, Daqian ZHANG, Jinlin HOU. Strategies and advances in targeting adaptive immunity to cure chronic hepatitis B[J]. Journal of Clinical Hepatology, 2021, 37(5): 1016-1021. doi: 10.3969/j.issn.1001-5256.2021.05.005
    [4]Hong ZHANG, Xiaoxue ZHU, Jiajia MAI, Hong CHEN, Jing ZHOU, Yue HU, Jia XU, Yanhua DING. Clinical studies of new antiviral drugs for chronic hepatitis B[J]. Journal of Clinical Hepatology, 2021, 37(5): 1006-1010. doi: 10.3969/j.issn.1001-5256.2021.05.003
    [5]Kaimin SONG, Jun LIU. Advances in the application of transient elastography in chronic hepatitis B[J]. Journal of Clinical Hepatology, 2021, 37(2): 419-424. doi: 10.3969/j.issn.1001-5256.2021.02.036
    [6]Xuefu CHEN, Dongjing ZHANG, Xiaodan LUO, Ren CHEN. Current status of the treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2021, 37(5): 1011-1015. doi: 10.3969/j.issn.1001-5256.2021.05.004
    [7]Weili NIU, Yongsu WANG, Qingshan WU, Lin ZHANG, Zhongqin ZHANG, Xiaojun YANG, Xianbin ZHU, Wenqin XIAO, Mingping JI. A clinical study of clinical cure after the addition of interferon therapy in chronic hepatitis B patients with low-level HBsAg previously treated with nucleos(t)ide analogues[J]. Journal of Clinical Hepatology, 2021, 37(8): 1793-1797. doi: 10.3969/j.issn.1001-5256.2021.08.010
    [8]Tian ZHANG, Sijing JIA, Dongxue SUN, Fengxi LONG, Dongxin TANG, Zhu YANG. Mechanism of "Szechwan Chinaberry Fruit-Rhizoma Corydalis" drug combination in treatment of liver cancer based on network pharmacology[J]. Journal of Clinical Hepatology, 2021, 37(9): 2136-2143. doi: 10.3969/j.issn.1001-5256.2021.09.026
    [9]Tingting ZHANG, Jue ZHAO, Yan YANG, Yaojie KANG, Xuan WANG. Type 1 diabetes mellitus due to pegylated interferon treatment of chronic hepatitis B: A case report[J]. Journal of Clinical Hepatology, 2021, 37(8): 1905-1906. doi: 10.3969/j.issn.1001-5256.2021.08.031
    [10]Qiuluo CHENG, Liu LIU, Changchuan BAI, Qingwei CONG, Ying ZHU. Mechanism of action of five classic prescriptions in treatment of hepatocellular carcinoma based on network pharmacology[J]. Journal of Clinical Hepatology, 2021, 37(8): 1848-1855. doi: 10.3969/j.issn.1001-5256.2021.08.020
    [11]Shaohang LAN, Qiuyuan TANG, Nana LI, Ran TAO, Nansheng LIAO, Yinjie MENG, Cao HE, Dewen MAO. Mechanism of action of Xiaochaihu decoction in the treatment of hepatitis B based on network pharmacology[J]. Journal of Clinical Hepatology, 2021, 37(10): 2308-2315. doi: 10.3969/j.issn.1001-5256.2021.10.010
    [12]Le TIAN, Yinghang WANG, Zhi PAN. Mechanism of Xiaozheng Huoluo prescription in preventing liver fibrosis in rats via the ERK5 pathway: An analysis based on network pharmacology[J]. Journal of Clinical Hepatology, 2021, 37(3): 582-589. doi: 10.3969/j.issn.1001-5256.2021.03.016
    [13]Jingshu QI, Dabing PING, Xin SUN, Jingbo XUE, Yanyan TAO, Yuan PENG, Chenghai LIU. Mechanism of action of Fuzheng Huayu prescription in treatment of liver cancer based on network pharmacology[J]. Journal of Clinical Hepatology, 2021, 37(10): 2338-2342. doi: 10.3969/j.issn.1001-5256.2021.10.016
    [14]Li Jing, Mo JiaHao, Xu HongBin, Zhu JunXia, Shi PeiYu, Xing WanLi, Zhong Chong, Lin LiZhu. Mechanism of action of Sini powder in treatment of liver cancer based on network pharmacology and molecular docking[J]. Journal of Clinical Hepatology, 2020, 36(9): 1998-2004. doi: 10.3969/j.issn.1001-5256.2020.09.018
    [15]Mu LiYa, Tang XiuFen, Li ShuQin, Yu Dan, Sun YuanYuan, Zhao JinHua. Clinical effects of bone marrow stem cell transplantation through different approaches in mice with acute liver injury[J]. Journal of Clinical Hepatology, 2019, 35(1): 153-156. doi: 10.3969/j.issn.1001-5256.2019.01.029
    [16]Lu Xin, Liu Ying, Jia Lei, Kong LingYu, Liu DianQing. Role of D-bifunctional protein in promoting the growth of hepatocellular carcinoma in rats and nude mice[J]. Journal of Clinical Hepatology, 2019, 35(7): 1532-1535. doi: 10.3969/j.issn.1001-5256.2019.07.022
    [17]Huang HaiYan, Xin YongNing, Jiang Man, Jin WenWen, Jiang XiangJun, Xuan ShiYing. Research advances in animal models of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2014, 30(9): 948-953. doi: 10.3969/j.issn.1001-5256.2014.09.028
    • Supplements(0)
    • Cited By
  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 18.6 %FULLTEXT: 18.6 %META: 73.3 %META: 73.3 %PDF: 8.0 %PDF: 8.0 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 7.7 %其他: 7.7 %其他: 1.7 %其他: 1.7 %China: 0.1 %China: 0.1 %India: 0.1 %India: 0.1 %Seattle: 0.1 %Seattle: 0.1 %[]: 0.3 %[]: 0.3 %上海: 5.6 %上海: 5.6 %东莞: 0.1 %东莞: 0.1 %中卫: 0.2 %中卫: 0.2 %乌鲁木齐: 0.1 %乌鲁木齐: 0.1 %佛山: 0.1 %佛山: 0.1 %兰州: 0.2 %兰州: 0.2 %北京: 3.7 %北京: 3.7 %南京: 0.2 %南京: 0.2 %南宁: 0.2 %南宁: 0.2 %南平: 0.1 %南平: 0.1 %南昌: 0.3 %南昌: 0.3 %南通: 0.2 %南通: 0.2 %南阳: 0.1 %南阳: 0.1 %卡纳塔克: 0.2 %卡纳塔克: 0.2 %台州: 1.7 %台州: 1.7 %合肥: 0.3 %合肥: 0.3 %吉林: 0.6 %吉林: 0.6 %吉隆坡: 0.3 %吉隆坡: 0.3 %哥伦布: 0.1 %哥伦布: 0.1 %嘉兴: 0.1 %嘉兴: 0.1 %大庆: 0.2 %大庆: 0.2 %天津: 0.6 %天津: 0.6 %安顺: 0.1 %安顺: 0.1 %宜春: 0.2 %宜春: 0.2 %常州: 4.0 %常州: 4.0 %常德: 0.1 %常德: 0.1 %广州: 0.5 %广州: 0.5 %开封: 0.1 %开封: 0.1 %弗吉: 0.1 %弗吉: 0.1 %张家口: 2.3 %张家口: 2.3 %徐州: 0.1 %徐州: 0.1 %成都: 0.2 %成都: 0.2 %拉斯维加斯: 0.1 %拉斯维加斯: 0.1 %无锡: 0.1 %无锡: 0.1 %昆明: 0.5 %昆明: 0.5 %杜塞尔多夫: 0.1 %杜塞尔多夫: 0.1 %杭州: 1.6 %杭州: 1.6 %武汉: 1.7 %武汉: 1.7 %济南: 0.2 %济南: 0.2 %海得拉巴: 0.2 %海得拉巴: 0.2 %深圳: 0.3 %深圳: 0.3 %湖州: 1.1 %湖州: 1.1 %湘潭: 0.1 %湘潭: 0.1 %漯河: 0.1 %漯河: 0.1 %潍坊: 0.7 %潍坊: 0.7 %红河哈尼族彝族自治州: 0.1 %红河哈尼族彝族自治州: 0.1 %罗奥尔凯埃: 0.2 %罗奥尔凯埃: 0.2 %芒廷维尤: 32.7 %芒廷维尤: 32.7 %芜湖: 0.1 %芜湖: 0.1 %芝加哥: 0.3 %芝加哥: 0.3 %苏州: 0.1 %苏州: 0.1 %莫斯科: 1.1 %莫斯科: 1.1 %衡水: 0.1 %衡水: 0.1 %衢州: 0.9 %衢州: 0.9 %西宁: 11.3 %西宁: 11.3 %西安: 0.5 %西安: 0.5 %贵阳: 0.3 %贵阳: 0.3 %赤峰: 0.3 %赤峰: 0.3 %达卡: 0.7 %达卡: 0.7 %运城: 2.0 %运城: 2.0 %郑州: 5.6 %郑州: 5.6 %重庆: 0.6 %重庆: 0.6 %金华: 0.2 %金华: 0.2 %长春: 0.8 %长春: 0.8 %长沙: 1.2 %长沙: 1.2 %长治: 0.1 %长治: 0.1 %首尔特别: 0.2 %首尔特别: 0.2 %麻坡: 0.1 %麻坡: 0.1 %其他其他ChinaIndiaSeattle[]上海东莞中卫乌鲁木齐佛山兰州北京南京南宁南平南昌南通南阳卡纳塔克台州合肥吉林吉隆坡哥伦布嘉兴大庆天津安顺宜春常州常德广州开封弗吉张家口徐州成都拉斯维加斯无锡昆明杜塞尔多夫杭州武汉济南海得拉巴深圳湖州湘潭漯河潍坊红河哈尼族彝族自治州罗奥尔凯埃芒廷维尤芜湖芝加哥苏州莫斯科衡水衢州西宁西安贵阳赤峰达卡运城郑州重庆金华长春长沙长治首尔特别麻坡

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (2122) PDF downloads(420) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[1659]YesterdayPV[2864]TodayIP[49]TodayPV[93]Online[18]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return